Jefferies Starts Pieris Pharmaceuticals (PIRS) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Nasdaq futures fall after record Samsung profit fails to calm AI chip worries
- Oil gains after vessel attacks near Strait of Hormuz
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Evercore ISI Starts Pieris Pharmaceuticals (PIRS) at Outperform
March 19, 2018 8:08 AM EDTEvercore ISI initiates coverage on Pieris Pharmaceuticals (NASDAQ: PIRS) with an Outperform rating and a price target of $13.00.
Analyst Umer Raffat and Akash Tewari note while the platform and the preclinical pipeline, they focused specifically on the two key programs:
1.... More
